Hemoglobinopathies Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The Hemoglobinopathies Treatment Market is Segmented by Treatment (Stem Cell Therapy, Blood Transfusion, Iron Chelation Therapy, Others), by Application, and Geography

Hemoglobinopathies Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Hemoglobinopathies Treatment Market Size

Hemoglobinopathies Treatment Market Overview
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Historical Data Period 2019 - 2022
CAGR 7.00 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Hemoglobinopathies Treatment Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Hemoglobinopathies Treatment Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Hemoglobinopathies Treatment Market Analysis

The global hemoglobinopathies treatment market was studied and projected to grow with a CAGR of nearly 7% over the forecast period. The growth is primarily due to an increase in the cases of hemoglobinopathies, coupled with growing awareness pertaining to hemoglobin disorders. According to the World Health Organization, about 1.1% of the couples globally are at the risk of having a child with hemoglobin disorder and prevalence was estimated at 2.55 per 1000. In addition, the presence of strong product pipeline for the treatment of hemoglobinopathies and continuous efforts from the market players and government in developing the new therapies for the same are anticipated to boost the market growth. However, low awareness related to the hemoglobinopathies in low and some of the middle-income countries is anticipated to hamper the market growth. Moreover, the initiatives such as newborn screening for detection of potential disorders are lead by the government and private organizations are anticipated to fuel the market growth for hemoglobinopathies treatment.

Hemoglobinopathies Treatment Industry Overview

Global hemoglobinopathies treatment market is moderately fragmented and competitive. Market players are focusing on new product launches, product innovations and geographical expansion. For instance, in May 2017, Sangamo Therapeutics and Pfizer announced a collaboration for the haemophilia A gene therapy. The key market players operating in the market include Sanofi S.A., Global Blood Therapeutics, Inc., bluebird bio, Inc. EMI Holding, Inc. and Celgene Corporation among others.

Hemoglobinopathies Treatment Market Leaders

  1. Sanofi S.A.

  2. Global Blood Therapeutics, Inc.

  3. bluebird bio, Inc.

  4. EMI Holding, Inc.

  5. Celgene Corporation

  6. *Disclaimer: Major Players sorted in no particular order
Sanofi S.A., Global Blood Therapeutics, Inc., bluebird bio, Inc. EMI Holding, Inc. Celgene Corporation
Need More Details on Market Players and Competiters?
Download PDF

Hemoglobinopathies Treatment Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Genetic Blood Disorders
    • 4.2.2 Presence of Robust Pipeline
  • 4.3 Market Restraints
    • 4.3.1 Low Awareness Regarding Hemoglobinopathies
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION

  • 5.1 By Treatment
    • 5.1.1 Stem Cell Therapy
    • 5.1.2 Blood Transfusion
    • 5.1.3 Iron Chelation Therapy
    • 5.1.4 Others
  • 5.2 By Application
    • 5.2.1 Thalassemia
    • 5.2.2 Sickle Cell Anaemia
    • 5.2.3 Others
  • 5.3 Geography
    • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
    • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Sanofi S.A.
    • 6.1.2 Global Blood Therapeutics, Inc.
    • 6.1.3 bluebird bio, Inc.
    • 6.1.4 EMI Holding, Inc.
    • 6.1.5 Celgene Corporation
    • 6.1.6 Gamida Cell
    • 6.1.7 Prolong Pharmaceuticals, LLC.
    • 6.1.8 Sangamo Therapeutics Inc.
    • 6.1.9 Silence Therapeutics
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Hemoglobinopathies Treatment Industry Segmentation

As per the scope of the report, hemoglobinopathies is the group of blood disorders which are inheritable, including thalassemia, sickle cell anaemia and others.

By Treatment Stem Cell Therapy
Blood Transfusion
Iron Chelation Therapy
Others
By Application Thalassemia
Sickle Cell Anaemia
Others
Geography North America United States
Canada
Mexico
Geography Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Geography Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Geography Middle-East and Africa GCC
South Africa
Rest of Middle-East and Africa
Geography South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Hemoglobinopathies Treatment Market Research FAQs

What is the current Hemoglobinopathies Treatment Market size?

The Hemoglobinopathies Treatment Market is projected to register a CAGR of 7% during the forecast period (2024-2029)

Who are the key players in Hemoglobinopathies Treatment Market?

Sanofi S.A., Global Blood Therapeutics, Inc., bluebird bio, Inc., EMI Holding, Inc. and Celgene Corporation are the major companies operating in the Hemoglobinopathies Treatment Market.

Which is the fastest growing region in Hemoglobinopathies Treatment Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).

Which region has the biggest share in Hemoglobinopathies Treatment Market?

In 2024, the North America accounts for the largest market share in Hemoglobinopathies Treatment Market.

What years does this Hemoglobinopathies Treatment Market cover?

The report covers the Hemoglobinopathies Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Hemoglobinopathies Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.

Hemoglobinopathies Treatment Industry Report

Statistics for the 2024 Hemoglobinopathies Treatment market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Hemoglobinopathies Treatment analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.